Our laboratory is interested in trying to understand why most people are healthy at a more molecular level. And we're also very interested in understanding when people get disease, and being a lung and ICU physician I am very interested in lung disease and critical care disease, what are the details of what goes wrong. We certainly want to accelerate the time it takes to take a discovery from the laboratory and apply it at the patient's bedside, and we know currently that's about 17 years if you look at the existing data.So by having a coordinated effort between doctors and researchers and educators, we have been able to take a disease that was really previously a fatal disease and now made it a chronic disease. And that really is directly related to focused funding from the National Institutes of Health and other entities that have facilitated and driven and focused people at this particular entity.
Clay Marsh, M.D. Professor, The Ohio State University, Columbus, Ohio Intracellular Pathways of Monocyte Survival Administered by the NHLBI Division of Lung Diseases, Lung Biology and Disease Branch FY 2009 Recovery Act Funding: $17,010
Interested in Recovery Act information? Join the NHLBI Research and Policy Update listserv to receive The NHLBI’s Recovery Act News e-newsletter and other updates. Join the listserv.
Did you get Recovery Act funding? Do you have a great story to tell? Let us know about it! E-mail nhlbi_news@nhlbi.nih.gov.